Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma

Journal of Biological Response Modifiers

Volumn 5, Issue 3, 1986, Pages 236-249

  McCarthy, W H ^e   Milton, G W ^e   Spurling, A ^a  

^a Oncology and Immunology Unit   (Australia)

^b ROYAL NEWCASTLE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Essex Laboratories Sydney ^*  (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Alpha 2 interferon; Disseminated melanoma; Natural killer activity

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; DACARBAZINE; INTERLEUKIN 2; POKEWEED MITOGEN; RADIOISOTOPE; RECOMBINANT INTERFERON;

ADULT; B LYMPHOCYTE; BLOOD AND HEMOPOIETIC SYSTEM; CLINICAL ARTICLE; DRUG COMPARISON; DRUG EFFICACY; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KILLER CELL; LYMPHATIC SYSTEM; MELANOMA; METASTASIS; METHODOLOGY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADULT; B-LYMPHOCYTES; CELLS, CULTURED; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; HYDROCORTISONE; IMMUNOTHERAPY; INTERFERON TYPE I; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0022900639     PISSN: 07326580     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutlerman JU. Alpha interferon for induction of remission in harly-cell leukaemia. N Engl J Med 1984;310:15-8.
2. Krown S, Burke M. Kirkwood JM, Kerr JJ, Nordlund JJ, Morton DS, Oettgen HF. Human leukocyte alpha interferon in metastatic malignant melanoma. The American Cancer Society Phase II Trial. Cancer Treat Rep 1984;68:723-6.
3. Ernstoff MS, Fusi S, Kirkwood JM. Parameters of interferon action. II. Immunological effects of recombinant leukocyte interferon (IFN-α2) in phase I-II trials. J Biol Response Mod 1983;2: 540-7.
4. Pouillart P. Bretaudeau B, Dorval T, Palangie T, Jouve M, Garcia-Giralt E, Falcoff E, Derstepani L. Clinical phase II study of recombinant DNA interferon (H.U. IFN-a2) in patients with metastatic malignant melanoma [Abstract]. Antiviral Res 1984;Sept. (No. 3):D19.
5. Groopman JE, Gottlieb MS, Goodman J. Mitsuyasu RT. Conant MA. Prince H. Fahey JC, Derezin M, Weintein WM. Casavante C. Rothman J, Rudnick SA. Volberding PA. Recombinant alpha-2 interferon therapy for kaposis sarcoma associated with the acquired immunodeficiency syndrome. Ann Int Med 1984;100:671-6.
6. Quesada JR, Gutterman JU. Clinical study of recombinant DNA-produced leukocyte (clone A) in an intermittent schedule in cancer patients. J Natl Cancer Inst 1983;70:1041-6.
7. Foon KA, Sherwin SA, Abrams PG, Longo DL, Fer MF. Stevenson HC. Ochs JJ. Bottino GC. Schoenaerger CS. Zeffren J, Jaffe ES, Oldham RK. Treatment of advanced non-Hodgkins lymphoma with recombinant leukocyte-A interferon. N Engl J Med 1984;311:114-8.
8. Creagan ET. Ahmann DL. Green SJ, Long HJ. Frytak S, O’Fallon JR. Itri LM. Phase II study of"low dose” recombinant leukocyte-A interferon (rlFN-aA) in disseminated malignant melanoma. Am J Clin Oncol 1984;2:1002-5
9. Creagan ET, Ahmann DL, Green SJ, Long HL, Rubin J. Schutt AJ. Dziewanoski ZE. Phase II study of recombinant leukocyte-A interferon (rlFN-aA) in disseminated malignant melanoma. Cancer 1984;54:2844-9.
10. Beaupain R, Billiard C, Falcoff E. Effects of human recombinant interferons and on growth and survival of human cancer cells maintained in continuous organotypic culture [Abstract], Antiviral Res 1984;3(Sept.):116.
11. Jonak GJ, Anton ED, Fahey D, Friedland BK, Cheng YSE, Knight E. Interferon-mediated regulation of the c myc oncogene expression in human cells and its relation to the inhibition of cell growth [Abstract]. Antiviral Res 1984;3(Sept.):24.
12. Toy, JL. The Interferons. Clin Exp Immunol 54:1-13.
13. Hersey P, Hasic E, MacDonald M, Edwards A, Spurling A. Coates AS, Milton GW, McCarthy WH. Effects of recombinant leukocyte interferon (rlFN-ctA) on tumor growth and immune responses in patients with metastatic melanoma. Br J Cancer 1985;51:815-26.
14. Coates A, Railings M. Hersey P, Swanson C. Phase II study of recombinant alpha-2 interferon in advanced malignant melanoma. J Interferon Res 1985;6:1-4.
15. Hersey P, Grace J, Murray E, Palmer A. McCarthy WH. Expression of Thy-1 antigen on human melanoma cells, Int J Cancer 1983;32:21-5.
16. Hersey P, Edwards A, McCarthy WH. Tumour-related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness, and age of patient. Int J Cancer 1980;25:187-94.
17. Hersey P, Bindon C, Edwards A, Murray E, Phillips C, McCarthy WH. Induction of cytotoxic activity in human lymphocytes against autologous and allogenic melanoma cells in vitro by culture with interleukin 2. Int J Cancer 1981;28:695-703.
18. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocytes-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1:51-63.
19. Suzuki R, Handa K, Itoh K, Kumagai K. Natural killer cells as a responder to interleukin 2 (1L2). Proliferative response and establishment of cloned cells. J Immunol 1983;130:981-7.
20. Hersey P. Ho K, Werkmeister J. Abele U. Inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures of T and B cells by levamisole in vitro and in vivo. Clin Exp Immunol 1981;46:340-9.
21. Silver HKB. Connors JM, Karim KA. King S. Spinelli JJ, de Jong G. McLean D. Salinas F. Effect of lymphoblastid interferon on lymphocyte subsets in cancer patients. J Biol Response Mod 1983;2:428-40.
22. Mittelman A, Krown SE. Cirrincione C. Safai B. Oettgen JF. Koziner B. Analysis of T-cell subsets in cancer patients treated with interferon. Am J Med 1983;75:966-72.
23. Hengst JCD, Kempf RA. Kan-Mitchell J, Pham ATH, Grunberg SM. Kortes VL, Mitchell MS. Immunological effects of recombinant interferon 2 in cancer patients. J Biol Response Mod 1983;2:516-27.
24. Golub SH, Dorey F, Hara D. Morton DL. Burke MW. Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell populations. J Natl Cancer Inst 1982;68:703-10.
25. Bash JA, Teitelbraum D, Sreevalsan T, Neefe JR. Immunomodulatory activities of human leukocyte interferon in advanced cancer patients. J Biol Resp Mod 1983;2:57-65.
26. Lotzova E. Savary CA, Quesada JR, Gutterman JU. Hersh EM. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon. J Natl Cancer Inst 1983;71:903-10.
27. Edwards BS. Hawkins MJ. Borden EC. Correlation between in vitro and systemic effects of native and recombinant interferons on human natural killer cell cytotoxicity. J Biol Response Mod 1983;2:409-17.
28. Maluish AE. Ortaldo JR. Conlon JC. Sherwin SA. Leavitt R. Strong DM. Weirnik P. Oldham RK. Herberman RD. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon. J Immunol 1983;131:503-7.
29. Grimm EA. Mazumder A. Zhang HZ. Rosenberg SA. Lymphokine-activaled killer cell phenomenon lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-aclivated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-41.
30. Cupps TR. Edgar LC. Thomas CA. Fauci AS. Multiple mechanisms of B cell immunoregulation in man after administration of in vivo corticosteroids. J Immunol 1984;132:170-5.
31. Gillis S, Crabtree GF. Smith KA. Glucocorticoid-induced inhibition of T-cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 1979;123:1624-31.